Hepatect Cp (Human Hepatitis B Immunoglobulin)

Hepatect Cp is indicated for specific situations where rapid protection against hepatitis B virus is required.

• Prophylaxis after accidental percutaneous or mucosal exposure to hepatitis B infected blood or body fluids.
• Prevention of mother‑to‑child transmission when the newborn has not received hepatitis B vaccine at birth.
• Prevention of hepatitis B recurrence in patients undergoing liver transplantation.
• Post‑exposure prophylaxis for individuals who are non‑immune and have been exposed to hepatitis B.
• Supplementary protection for patients with chronic liver disease who are at high risk of hepatitis B infection.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common

• Mild fever, chills, or rigors occurring during or shortly after the infusion.
• Headache, nausea, or transient abdominal discomfort that resolves without intervention.
• Localized infusion‑site reactions such as erythema, swelling, or a brief feeling of warmth.

Serious

• Severe hypersensitivity reactions including anaphylaxis, characterized by respiratory distress, urticaria, or hypotension.
• Aseptic meningitis presenting with headache, neck stiffness, and photophobia after infusion.
• Renal impairment or hemolysis indicated by reduced urine output, elevated creatinine, or hemoglobinuria.

When using Hepatect Cp, clinicians should consider several precautionary measures to ensure patient safety.

• Assess patient’s immunoglobulin tolerance and history of allergic reactions before infusion.
• Monitor vital signs and observe for signs of hypersensitivity during the first 30 minutes of administration.
• Adjust dosage or infusion rate in patients with renal insufficiency or cardiovascular disease.
• Avoid use in individuals with known IgA deficiency who have anti‑IgA antibodies.
• Ensure hepatitis B vaccination status is documented; Hepatect Cp does not replace active immunization.
• Use caution in pregnant or breastfeeding women; limited safety data are available.

Hepatect Cp may interact with other medications or clinical conditions, requiring attention to avoid adverse outcomes.

Avoid

• Concurrent administration of other blood‑derived products (e.g., plasma, albumin) without appropriate monitoring.
• Live vaccines administered within 4 weeks of Hepatect Cp infusion.

Use with caution

• Immunosuppressive agents such as corticosteroids or biologics that may alter immune response.
• Anticoagulants, because rapid infusion can affect coagulation parameters.
• Diuretics or nephrotoxic drugs in patients with compromised renal function.